Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways

Carcinogenesis

Volumn 32, Issue 9, 2011, Pages 1372-1380

  Prakobwong, Suksanti ^a,b   Gupta, Subash C ^b   Kim, Ji Hye ^b   Sung, Bokyung ^b   Pinlaor, Porntip ^a   Hiraku, Yusuke ^c   Wongkham, Sopit ^a   Sripa, Banchob ^a   Pinlaor, Somchai ^a   Aggarwal, Bharat B ^b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CURCUMIN; CYCLIN D1; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DNA; ESTERASE; FLICE INHIBITORY PROTEIN; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; JANUS KINASE 1; MYC PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIDOREDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLSERINE; PROTEIN BCL 2; PROTEIN BCL XL; SERINE; STAT3 PROTEIN; SURVIVIN; SYNAPTOTAGMIN I; TYROSINE; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BILE DUCT CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 80052410901     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr032     Document Type: Article

References (49)

1. Gores,G.J. (2003) Cholangiocarcinoma: current concepts and insights. Hepatology, 37, 961-969.
2. Lazaridis,K.N. et al. (2005) Cholangiocarcinoma. Gastroenterology, 128, 1655-1667.
3. Vatanasapt,V. et al. (1990) Cholangiocarcinoma in north-east Thailand. Lancet, 335, 116-117.
4. Sirica,A.E. (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology, 41, 5-15.
5. Karin,M. (2006) Nuclear factor-kappaB in cancer development and progression. Nature, 441, 431-436.
6. Orlowski,R.Z. et al. (2002) NF-kappaB as a therapeutic target in cancer. Trends Mol. Med., 8, 385-389.
7. Fabre,C. et al. (2008) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle, 7, 2139-2145.
8. Lu,T. et al. (2004) Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle, 3, 1114-1117.
9. Weisz,L. et al. (2007)Mutant .p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. Cancer Res., 67, 2396-2401.
10. Zhang,X. et al. (2007) The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr. Cancer Drug Targets, 7, 305-316.
11. Beg,A.A. et al. (1996) An essential role for NF-kappaB in preventing TNFalpha-induced cell death. Science, 274, 782-784.
12. Aggarwal,B.B. (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell, 6, 203-208.
13. Catlett-Falcone,R. et al. (1999) Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity, 10, 105-115.
14. Masuda,M. et al. (2002) Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res., 62, 3351-3355.
15. Xie,T.X. et al. (2004) Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene, 23, 3550-3560.
16. Niu,G. et al. (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene, 21, 2000-2008.
17. Mangelsdorf,D.J. et al. (1995) The nuclear receptor superfamily: the second decade. Cell, 83, 835-839.
18. Kobuke,T. et al. (2006) A Ligand for peroxisome proliferator-activated receptor gamma inhibits human cholangiocarcinoma cell growth: potential molecular targeting strategy for cholangioma. Dig. Dis. Sci., 51, 1650-1657.
19. Sarraf,P. et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med., 4, 1046-1052.
20. Gupta,S.C. et al. (2010) Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev., 29, 405-434.
21. Newman,D.J. et al. (2003) Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod., 66, 1022-1037.
22. Aggarwal,B.B. et al. (2006) Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol., 71, 1397-1421.
23. Zhang,F. et al. (1999) Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis, 20, 445-451.
24. Bharti,A.C. et al. (2004) Evidence that receptor activator of nuclear factor (NF)-kappaB ligand can suppress cell proliferation and induce apoptosis through activation of a NF-kappaB-independent and TRAF6-dependent mechanism. J. Biol. Chem., 279, 6065-6076.
25. Gupta,S.C. et al. (2010) Modification of cysteine-179 of IkappaBalpha kinase by Nimbolide leads to downregulation of NF-kappaB-regulated cell survival and proliferative proteins and sensitization of tumor cells to chemotherapeutic agents. J. Biol. Chem, 285, 35406-35417.
26. Sethi,G. et al. (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaBregulated gene products and TAK1-mediated NF-kappaB activation. Blood, 109, 2727-2735.
27. Bharti,A.C. et al. (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood, 101, 1053-1062.
28. Plummer,S.M. et al. (1999) Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene, 18, 6013-6020.
29. Sandur,S.K. et al. (2009) Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys., 75, 534-542.
30. Isomoto,H. et al. (2007) Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology, 132, 384-396.
31. Taniai,M. et al. (2004) Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res., 64, 3517-3524.
32. Aggarwal,B.B. et al. (2006) Targeting signal-transducer-and-activator-oftranscription-3 for prevention and therapy of cancer: modern target but ancient solution. Ann. N. Y. Acad. Sci., 1091, 151-169.
33. Prakobwong,S. et al. (2010) Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. Int. J. Cancer, in press, doi:20824699.
34. Zushi,S. et al. (1998) STAT3 mediates the survival signal in oncogenic rastransfected intestinal epithelial cells. Int. J. Cancer., 78, 326-330.
35. Mahboubi,K. et al. (2001) Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab. Invest., 81, 327-334.
36. Bhattacharya,S. et al. (2003) Regulation of Stat3 nuclear export. J. Clin. Invest., 111, 553-559.
37. Aoki,Y. et al. (2003) Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood, 101, 1535-1542.
38. Aggarwal,B.B. et al. (2009) Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res., 15, 425-430.
39. Pinlaor,S. et al. (2006) iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel. Int. J. Cancer., 119, 1067-1072.
40. Seubwai,W. et al. (2010) Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB. Cancer Sci., 101, 1590-1595.
41. Zong,W.X. et al. (1999) The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis. Genes Dev., 13, 382-387.
42. Tamatani,M. et al. (1999) Tumor necrosis factor induces Bcl-2 and Bcl-x expression through NFkappaB activation in primary hippocampal neurons. J. Biol. Chem., 274, 8531-8538.
43. Stehlik,C. et al. (1998) Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J. Exp. Med., 188, 211-216.
44. Wang,C.Y. et al. (1998) NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science, 281, 1680-1683.
45. Zhu,L. et al. (2001) Anti-apoptotic protein survivin plays a significant role in tubular morphogenesis of human coronary arteriolar endothelial cells by hypoxic preconditioning. FEBS Lett., 508, 369-374.
46. Simonian,P.L. et al. (1997) Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood, 90, 1208-1216.
47. Onori,P. et al. (2009) Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int. J. Cancer., 125, 565-576.
48. Pawar,P. et al. (2009) Molecular mechanisms of tamoxifen therapy for cholangiocarcinoma: role of calmodulin. Clin. Cancer Res., 15, 1288-1296.
49. Mukhopadhyay,A. et al. (2002) Curcumin-induced suppression of cell proliferation correlates with down-regulation of cyclin D1 expression and CDK4-mediated retinoblastoma protein phosphorylation. Oncogene, 21, 8852-8861.